NYSE · QGEN
Healthcare · Medical - Diagnostics & Research
$43.39
Up+$0.81 (+1.87%)
Updated Sep 2, 2026, 8:49 PM
SID Score
5.5/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
QGEN closed at $43.39 after 21 trading sessions, up 2.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $44.23 | $44.32 | $43.08 | $43.39 | 2.55M |
| Aug 31, 2026 | $43.04 | $43.48 | $42.57 | $43.29 | 1.35M |
| Aug 28, 2026 | $43.62 | $43.99 | $42.99 | $43.11 | 1.38M |
| Aug 27, 2026 | $43.63 | $44.18 | $43.63 | $43.74 | 1.58M |
| Aug 26, 2026 | $43.37 | $43.865 | $43.225 | $43.36 | 1.54M |
| Aug 25, 2026 | $42.18 | $44.21 | $42.115 | $43.65 | 4.07M |
| Aug 24, 2026 | $43.95 | $44.06 | $41.42 | $41.78 | 8.62M |
| Aug 21, 2026 | $44.39 | $44.47 | $43.78 | $44.07 | 3.3M |
| Aug 20, 2026 | $44.21 | $45.53 | $44.20 | $44.90 | 4.8M |
| Aug 19, 2026 | $43.44 | $44.82 | $43.39 | $44.50 | 4.81M |
| Aug 18, 2026 | $43.06 | $43.46 | $42.32 | $42.32 | 2.75M |
| Aug 17, 2026 | $42.43 | $43.06 | $42.43 | $42.60 | 3.2M |
| Aug 14, 2026 | $43.55 | $43.725 | $42.77 | $42.95 | 3.67M |
| Aug 13, 2026 | $43.54 | $43.79 | $43.05 | $43.23 | 3.18M |
| Aug 12, 2026 | $42.21 | $43.07 | $42.14 | $43.00 | 3.53M |
| Aug 11, 2026 | $43.40 | $43.46 | $42.605 | $42.65 | 3.78M |
| Aug 10, 2026 | $43.12 | $44.41 | $43.12 | $43.85 | 2.97M |
| Aug 7, 2026 | $42.51 | $42.555 | $41.96 | $42.30 | 3.8M |
| Aug 6, 2026 | $42.38 | $42.50 | $40.87 | $41.73 | 4.03M |
| Aug 5, 2026 | $42.33 | $42.41 | $41.47 | $41.95 | 2.04M |
| Aug 4, 2026 | $42.14 | $42.36 | $41.40 | $42.33 | 3.36M |
The latest Smart Investors Daily articles mentioning QGEN.
QGEN research
Company profile and research snapshot.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Citigroup | Neutral | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
| Jun 23, 2026 | Morgan Stanley | Overweight | — |
| May 18, 2026 | Stifel | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science
Benzinga · Aug 24, 2026
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of
Yahoo · Aug 14, 2026
Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year guidance, along with FDA clearance for its QIAstat Dx BCID GPF Plus AMR Panel. See our latest analysis for Qiagen. The recent Q2 beat, reaffirmed guidance and FDA clearance appear to have supported sentiment in Qiagen, with the stock at US$43.23 and a 90 day share price return of 31.08% contrasting with a year to date share price decline of 9.12% and a 1 year total...
Yahoo · Aug 13, 2026
Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company’s own outlook. For a diagnostics and life sciences supplier still working through the loss of […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QGEN.
